Stock Pick

2 ASX small-caps with 50% and 270% upside according to Brokers

Written by

openjargon

in

Happy woman working on a laptop.

ASX small-caps can be a high upside allocation for an investor’s portfolio. 

While diversification and long-term principles should still be the fundamental base of a healthy strategy, ASX small-caps can provide increased potential compared to blue-chip stocks.

For investors looking to monitor smaller companies with big potential, brokers have tipped these two options to rise significantly.

Biome Australia Ltd (ASX: BIO)

Biome Australia develops and commercialises clinically backed innovative live biotherapeutics (probiotics), marketing 18 products under the ‘Activated Probiotics’ Brand. 

As is the case with small-caps, it has experienced plenty of volatility recently. 

It was making headlines yesterday after rocketing 20% in a single session after signing a new manufacturing agreement.

In a new report from Bell Potter, the broker has predicted this rise can continue in the next 12 months. 

The broker has a $1.00 price target on this ASX small-cap, indicating a massive 270% upside from current levels. 

In the report, Bell Potter highlighted that Biome Australia has announced an initiative to derisk and diversify its supply chain. The company is doing this by introducing contract manufacturing in its home market of Australia of assembly and packaging of its Activated Probiotics range. 

The initial two-year term with Specialty Probiotics Australia (SPA) is on an exclusive basis. It is subject to limited carve outs and meeting quality and delivery standards.

Conceptually, this is a positive and material development that should enhance operating leverage and BIO’s capacity to plan for growth, which has been impeded to some degree by relying completely on importing finished product. Assuming BIO continues to build its domestic franchise, we can see a path to $100m in Australian sales, with attractive margins.

Imricor Medical Systems Inc (ASX: IMR)

Imricor Medical Systems is a medical device company. It engages in the design, manufacture, and distribution of magnetic resonance imaging (MRI) compatible products for cardiac catheter ablation procedures.

It has also experienced volatility in 2026, but remains up 6% year to date. 

The team at Morgans believes this ASX small-cap could be an upside play. 

There are multiple near-term catalysts approaching which when achieved will see a share price re-rating. IMR is now well funded to deliver on clinical, regulatory, and commercial objectives. We have updated our model and valuation for the capital raise. Our target price is A$2.61 (was $2.63). We maintain our SPECULATIVE BUY recommendation.

From yesterday’s closing price of $1.74, the price target from Morgans indicates a 50% upside for this ASX small-cap. 

The post 2 ASX small-caps with 50% and 270% upside according to Brokers appeared first on The Motley Fool Australia.

Should you invest $1,000 in Biome Australia right now?

Before you buy Biome Australia shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Biome Australia wasn’t one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys…

See the 5 Stocks

* Returns as of 20 Feb 2026

.custom-cta-button p {
margin-bottom: 0 !important;
}

More reading

Motley Fool contributor Aaron Bell has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More posts